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Abstract 
 
F-box and WD repeat domain-containing 7α 
(Fbw7α) is the substrate recognition component of 
a ubiquitin ligase that controls the degradation of 
factors involved in cellular growth, including 
c-Myc, cyclin E, and c-Jun.  In addition, Fbw7α 
degrades the nuclear form of sterol regulatory 
element binding protein (SREBP)-1a, a global 
regulator of lipid synthesis, particularly during 
mitosis in cultured cells.  This study investigated 
the in vivo role of Fbw7α in hepatic lipid 
metabolism.  siRNA knockdown of Fbw7α in 
mice caused marked hepatosteatosis with the 
accumulation of triglycerides (TGs).  However, 
inhibition of Fbw7α did not change the level of 
nuclear SREBP-1 protein or the expression of 
genes involved in fatty acid synthesis and 
oxidation.  In vivo experiments on the gain and 
loss of Fbw7α function indicated that Fbw7α 
regulated the expression of peroxisome 
proliferator-activated receptor (PPAR) γ2 and its 
target genes involved in fatty acid uptake and 
triglyceride synthesis.  These genes included fatty 
acid transporter CD36, diacylglycerol 
acyltransferase 1 (DGAT1), and fat-specific 
protein 27 (Fsp27).  The regulation of PPARγ2 by 
Fbw7α was mediated, at least in part, by the direct 
degradation of the Krüppel-like factor 5 (KLF5) 
protein, upstream of PPARγ2 expression.  Hepatic 
Fbw7α contributes to normal fatty acid and 
triglyceride metabolism, functions which 
represent novel aspects of this cell growth 
regulator. 
 
Introduction 
 
F-box and WD repeat domain-containing 7 
(Fbw7) is the component of an evolutionary 
conserved complex of the Skp1-Cul1-F-box 
protein ubiquitin ligase (SCF) and is involved in 
substrate recognition of the complex (1,2).  Fbw7 
targets several proto-oncogenes that function in 
cell growth and division pathways, including 
c-Myc, cyclin E, Notch, and c-Jun (3-7).  Fbw7, is 
perturbed in many human malignancies and is an 
established tumor suppressor (8-11).  Mouse 
Fbw7 exists in three different isoforms: α, β, and γ.  
The α isoform is expressed ubiquitously, whereas 
the β and γ isoforms are restrictedly expressed in 
the brain, heart, testis, and skeletal muscle (12). 
Intriguing characteristics of Fbw7α have recently 
been described by Ericsson et al. who 
demonstrated that this cell growth regulator also 
regulated the degradation of the nuclear forms of 
the sterol regulatory element binding protein 
(SREBP) family (13,14). 
 SREBPs, belonging to the bHLH-Zip 
transcription factor family, are established 
regulators of lipid synthesis.  The unique features 
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of SREBPs are their rER membrane-bound 
transcription factors.  These factors need to 
undergo proteolytic cleavage for nuclear transport 
to activate the expression of genes involved in 
lipid synthesis. This represents the crucial step for 
sterol and fatty acid synthetic gene regulation 
(15-17).  The SREBP family includes three 
isoforms: SREBP-1a, -1c, and -2 (18-20). 
SREBP-2 governs cellular sterol regulation, 
whereas hepatic SREBP-1c controls fatty acid and 
triglyceride synthesis depending on the nutritional 
state of the liver.  SREBP-1a is highly expressed 
in growing cells and contributes to the synthesis 
of cholesterol, triglyceride (TG), and phospholipid 
for the supply of membrane lipids during cell 
growth (21,22). Nuclear SREBP-1a regulates the 
cell cycle and growth by itself, indicating its 
strong association with cell growth (23,24). 
 Without a proteasome inhibitor such as calpain 
inhibitor I in cell cultures, nuclear SREBPs are 
rapidly degraded by the ubiquitin–proteasome 
pathway after cleavage.  Recently, Fbw7 was 
reported to be the key factor for this degradation 
of SREBPs in cultured cells (14).  SREBP-1a is 
phosphorylated at several sites depending on the 
cell cycle and then degraded by the 
ubiquitin–proteasome system.  During mitosis, 
nuclear SREBP-1a is stabilized, and it activates 
lipid synthesis to supply membrane lipids (25). 
Thus, Fbw7 controls the degradation of SREBPs 
in cultured cells in relation to the cell cycle and 
growth.  However, its physiological roles in vivo 
are yet to be determined.  In the present study, the 
effects of Fbw7α modification on SREBPs and 
lipid metabolism in the liver were investigated. 
 
Experimental procedures 
 
 Materials - Antibodies to phosphorylated c-Jun 
(Ser63) and Lamin A/C were obtained from Cell 
Signaling Technology (Beverly, MA USA); 
antibodies to SREBP-1, c-Jun, Krüppel-like factor 
5 (KLF5), and α-tubulin were obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA USA), and 
that to Fbw7/hCdc4 was purchased from Abcam 
(Tokyo, Japan).  
N-acetyl-Leu-Leu-norleucinal-CHO (ALLN; 
calpain inhibitor I) and fenofibrate were 
purchased from Sigma (St. Louis, MO USA), 
redivue [α-32P]dCTP from GE Healthcare UK Ltd. 
(Buckinghamshire, England), and [1-14C]palmitate 
from PerkinElmer Life Sciences (Waltham, MA 
USA).  Restriction enzymes were obtained from 
Takara Bio Inc. (Shiga, Japan), and plasmid 
DNAs for transfection were prepared using the 
Qiagen Plasmid Midi Kit (Qiagen, Hilden, 
Germany). 
 Animal experiments - All animal studies were 
approved by the Animal Care Committee of the 
University of Tsukuba.  Male C57BL/6J mice (9- 
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and 14-week-old) were purchased from Clea 
(Tokyo, Japan), and male B6.V-Lep ob/J (ob/ob) 
mice (7-week-old) were obtained from Charles 
River (Kanagawa, Japan).  SREBP transgenic 
mice (13-week-old) overexpressing the active 
form of human SREBP-1c under the control of the 
rat phosphoenolpyruvate carboxykinase (PEPCK) 
promoter (SREBP1c-Tg) were generated as 
described previously (26).  In addition, SREBP-1 
knockout mice (SREBP1-KO) (6–8-week-old) 
were generated as described previously (27).  
KLF5 flox mice, in which the second exon was 
flanked by two lox sites, were also prepared and 
established (Ema M, manuscript in preparation).  
The mice were housed in colony cages, 
maintained on a 12-h light/12-h dark cycle, given 
free access to water and standard chow diet 
(Oriental Yeast, Tokyo, Japan); the mice were 
adapted to their new environment for at least one 
week prior to the experiments.  After the 
adenovirus injection, the mice were housed during 
the periods indicated and then sacrificed in the 
non-fasted state.  Tissues were isolated 
immediately, weighed, and stored in liquid 
nitrogen.  Plasma metabolic parameters were 
measured by using commercial kits according to 
the manufacturer’s instructions (all test kits were 
obtained from Wako Pure Chemical Industries, 
Osaka, Japan). 
 Preparation of recombinant adenovirus - We 
subcloned Fbw7-specific RNAi constructs using 
the Fbw7 coding sequence 
5′-GCTGAAACTGGAGAGTGTA-3′ into a U6 
entry vector (Invitrogen, Carlsbad, CA USA).  We 
then generated the recombinant adenoviral 
plasmid by homologous recombination with a 
pAd promoterless vector (Invitrogen).  Next, we 
subcloned peroxisome proliferator-activated 
receptor (PPAR) γ2-specific RNAi constructs 
using the PPARγ2 coding sequence 
5′-GCCTATGAGCACTTCACAA-3′ and 
generated the recombinant adenoviral plasmid as 
described above.  We subcloned 
hemagglutinin-tagged mouse Fbw7α cDNA into 
the pENTR4 vector (Invitrogen) and generated a 
recombinant adenoviral plasmid by homologous 
recombination with a pAd/CMV/V5-DEST vector 
(Invitrogen).  We produced recombinant 
adenoviruses in HEK-293 cells and purified them 
by CsCl gradient centrifugation, as described 
previously (28,29).  The recombinant adenovirus 
expressing the Cre recombinase AxCANCre was 
produced by Dr. Izumu Saito (Institute of Medical 
Science, University of Tokyo, Japan) and was 
obtained from Riken DNA Bank (Tsukuba, 
Japan). 
 RNA extraction, northern blot analysis, and 
quantitative real-time PCR - Total RNA was 
isolated from mouse livers and primary 
hepatocytes using the Sepazol RNA I Super 
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reagent (Nacalai Tesque Inc., Kyoto, Japan).  
Northern blot analysis was performed using the 
indicated 32P-labeled probe, as described 
previously (28,30).  First-strand cDNA was 
synthesized using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster 
City, CA USA), and comparative analysis of 
mRNA levels was performed using 
fluorescence-based real-time PCR. Real-time PCR 
analyses were performed using the ABI 7300 PCR 
system (Applied Biosystems).  Quantification of 
fat-specific protein 27 (Fsp27) was performed 
using a Taqman gene expression assay (Applied 
Biosystems), while quantification of other genes 
was performed using the SYBR-Green Dye 
(Nippon Gene, Tokyo, Japan).  The relative 
abundance of each transcript was calculated using 
a standard curve of cycle thresholds for serial 
dilutions of a cDNA sample and then normalized 
to cyclophilin levels (31).  The expression levels 
of cyclophilin used as an internal control in each 
experiment were not affected by procedures such 
as siRNA transfection.  Primer sequences are 
described in Supplementary Table S1. 
 Measurement of metabolic parameters - We 
measured the plasma levels of glucose, insulin, 
non-esterified fatty acid (NEFA), TG, total 
cholesterol (TC), aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT) as 
well as the levels of TG and TC in the liver, as 
described previously (32). 
 Expression plasmids - The expression plasmid for 
the human nuclear form of SREBP-1c has been 
described previously (33).  Expression plasmids 
encoding mouse Fbw7α and KLF5 were generated 
by PCR amplification, followed by the insertion 
of cDNAs into pcDNA3.1(+) (Promega).  The 
following primers were used: Fbw7α, 5′-primer 
5′-CTTAAGCTTGCCACCATGAATCAGGAAC
TGCTCTCTGT-3′, 3′-primer 
5′-CCGGAATTCTCATTTCATGTCCACATCA
AAGTCCAG-3′ and KLF5, 5′-primer 
5′-CTTAAGCTTGCCACCATGCCCACGCGGG
TGC-3′, 3′-primer 
5′-CCGGAATTCTCAGTTCTGGTGGCGCT-3′. 
Restriction sites HindIII and EcoRI were added to 
each 5′-primer and 3′-primer, respectively.  PCR 
products were digested with HindIII and EcoRI, 
and then inserted into the respective sites of 
pcDNA3.1(+).  Ligation was performed using a 
Quick Ligation Kit (New England Biolabs Inc., 
Ipswich, MA USA). 
 Cell cultures - Cos-7 cells were cultured in 
DMEM (Sigma) supplemented with 5% FBS and 
1% penicillin–streptomycin (Sigma).  For the 
KLF5 degradation assay, Cos-7 cells were seeded 
24 h before transfection in 6-cm plates at a density 
of 3 × 105 cells/plate.  Mouse primary hepatocytes 
were isolated from male C57BL/6J mice, as 
described previously (28) and seeded in 10-cm 
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plates for adenovirus infection and measurement 
of palmitate uptake. 
 Cellular uptake of [1-14C]palmitate - 
[1-14C]palmitate uptake by primary hepatocytes 
was measured as described previously, but with 
some modifications (34).  Briefly, the isolated 
hepatocytes were infected with adenovirus for 60 
h and incubated for 3 h in a culture medium 
containing 200 µM palmitate, radiolabeled 
[1-14C]palmitate (0.1 µCi/ml), 2 µM insulin, and 
1% BSA (Sigma).  After the 3-h incubation, the 
cells were washed twice with ice-cold PBS and 
then scraped into it.  Cellular lipids were extracted 
with chloroform/methanol as described by Bligh 
and Dyer (35), and the residual radioactivity of 
each sample was then determined. 
 KLF5 degradation assay - Each indicated 
expression plasmid (3 µg) was transfected into 
Cos-7 cells using the FuGENE 6 reagent (Roche 
Applied Science, Basel, Switzerland), according 
to the manufacturer’s instructions.  After 36 h of 
transfection, the cells were treated with 
cycloheximide (100 µg/mL) to stop protein 
synthesis and then incubated with or without 
ALLN for the indicated times. 
 Immunoblot analysis - We performed an 
immunoblot analysis using the antibodies 
indicated as described previously (29,36,37).  The 
intensity of each detected band was quantified 
using the image processing software ImageJ 
(National Institute of Mental Health, Bethesda, 
MD USA). 
 Liver histology - Mouse livers were fixed in 10% 
neutral buffered formalin and embedded in 
paraffin. The sections were subjected to standard 
hematoxylin and eosin staining. 
 Statistical analyses - All data are expressed as 
mean ± standard error of the mean (SEM). 
Statistical analyses were performed using 
unpaired Student’s t-test, one sample t-test, or 
two-way ANOVA, followed by Tukey’s 
procedure. 
 
Results 
 
To estimate the contribution of Fbw7 to the 
physiological regulation of hepatic SREBP-1c and 
hepatic lipogenesis, Fbw7 was knocked down in 
murine livers by intravenous injection of 
adenovirus producing Fbw7 siRNA (Fbw7i).  We 
confirmed that only the Fbw7α isoform was 
expressed in murine livers and cultured hepatoma 
cells, and Fbw7i fully suppressed Fbw7α 
expression in cultured hepatoma cells, as 
estimated by quantitative real-time PCR (data not 
shown).  In livers of mice infected with Fbw7i, the 
decrease in Fbw7α level was approximately 70% 
(Figure 1A). This hepatic Fbw7 knockdown 
caused fatty liver and a slight, but significant, 
enlargement of the liver (Figures 1B and 1C). 
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These mice exhibited no significant changes in 
food intake, white adipose tissue weight, or body 
weight compared to animals infected with 
adenovirus producing LacZ siRNA (LacZi) as a 
control (Figure 1D and data not shown).  Of the 
plasma metabolic parameters, TG, glucose, and 
insulin levels were reduced significantly by 
infection with Fbw7i (Table 1).  These data 
indicated that fatty liver was not likely to be 
associated with overnutrition or obesity. 
Hepatosteatosis was confirmed by liver histology 
(Figure 1E) with a marked increase in the liver 
content of TG (Figure 1F), but not TC (Figure 
1G). 
 Immunoblot analysis of hepatic nuclear extracts 
demonstrated that the increase in nuclear 
SREBP-1 protein by Fbw7 knockdown was 
minimal whereas c-Jun protein, another target of 
Fbw7, accumulated markedly without a change in 
its mRNA level (Figures 2A and 2B).  This 
finding confirmed Fbw7 inactivation.  The 
precursor form of SREBP-1c in the whole cell 
fraction did not change noticeably.  Lack of 
hepatic SREBP-1 activation by Fbw7α 
suppression was confirmed by the gene expression 
pattern estimated by real-time PCR (Figure 2C). 
With the exception of stearoyl-CoA desaturase 1 
(SCD1), mRNA levels of SREBP-1c and 
SREBP-1 target genes involved in fatty acid 
synthesis such as acetyl-CoA carboxylase, fatty 
acid synthase (FAS), and long chain fatty acid 
elongase 6 (Elovl6) were not up-regulated.  There 
were no changes in the expression of carbohydrate 
response element binding protein, another 
transcription factor that controls fatty acid 
synthesis (Figure 2C).  The mRNA levels of 
PPARα, a crucial regulator of hepatic fatty acid 
oxidation enzymes, and the PPARα target genes 
acyl-CoA oxidase and medium chain acyl-CoA 
dehydrogenase did not change (Figure 2D).  In 
contrast, hepatic expression of PPARγ2 increased 
significantly by Fbw7 knockdown, while 
expression of PPARγ1 increased minimally.  
Consistent with these findings, the expression of 
aP2, another PPARγ2 target gene, was also 
up-regulated (Figure 2E).  We observed marked 
increases in the mRNA levels of CD36, a 
transporter involved in the hepatic uptake of 
plasma fatty acids, mitochondrial 
glycerol-3-phosphate acyltransferase (GPAT), and 
diacylglycerol acyltransferase 1 (DGAT1), an 
enzyme in TG synthesis (Figure 2F).  
Fsp27/CIDE-C, a lipid droplet binding protein 
known to promote lipid accumulation in 
adipocytes, has recently been reported to 
contribute to hepatosteatosis as a PPARγ target 
(38-40).  Furthermore, the expression of Fsp27 
was enhanced by Fbw7 knockdown (Figure 2F).  
These data indicated that fatty liver induced by 
Fbw7 knockdown was caused by an elevation in 
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fatty acid uptake, TG synthesis, and lipid 
accumulation, rather than by an increase in de 
novo fatty acid synthesis or a decrease in fatty 
acid degradation.  These genes involved in the 
accumulation of TG are direct targets of PPARγ2. 
Consistent with the liver cholesterol content 
remaining unchanged, SREBP-2 target genes 
involved in cholesterol metabolism such as low 
density lipoprotein receptor (LDLR) and 
HMG-CoA reductase (HMGCR) did not change 
with Fbw7 knockdown (Figure 3A). 
Apolipoprotein B and microsomal triglyceride 
transfer protein involved in TG secretion did not 
decrease (Figure 3B).  Expression of 
gluconeogenic genes such as PEPCK, 
glucose-6-phosphatase, and glucose transporter 2 
did not change, while glucokinase expression 
decreased significantly by Fbw7 knockdown 
(Figure 3C).  Phosphorylated protein levels of 
c-Jun increased by Fbw7 knockdown (Figure 2A).  
Expression of cytokines such as IL-1β and IL-6 
did not change (Figure 3D). 
 The possibility that SREBP-1 did not contribute 
to fatty liver induced by Fbw7 knockdown was 
investigated further in SREBP1-KO.  Littermates 
and SREBP1-KO had similar basal mRNA levels 
of Fbw7α (Figure 4A).  After Fbw7 knockdown, 
the TG content of SREBP1-KO livers increased to 
levels comparable to littermates (Figure 4B). 
Inhibition of Fbw7 function by knockdown was 
confirmed by the increased levels of c-Jun and 
phosphorylated c-Jun proteins in nuclear extracts 
(Figure 4C).  Lipogenic enzyme genes such as 
FAS and SCD1 were not affected by Fbw7 
knockdown in SREBP1-KO livers (Figure 4D).  
Fbw7 knockdown did not alter HMGCR 
expression or liver cholesterol content (Figure 4E 
and data not shown).  Meanwhile, PPARγ2 and 
CD36 were up-regulated by Fbw7 knockdown 
irrespective of the presence or absence of 
SREBP-1 (Figure 4F), indicating 
SREBP-1c-independent and PPARγ2-mediated 
TG accumulation. 
 Besides its stability in the nucleus, nuclear 
SREBP-1c protein level is regulated mainly by its 
mRNA level and cleavage activity of the 
precursor SREBP-1c protein for nuclear transport.  
To exclude the possibility that the lack of change 
in the nuclear SREBP-1 protein by Fbw7 
knockdown was attributable to changes in mRNA 
expression and cleavage activity of the precursor 
protein, we tested the effect of Fbw7 inhibition on 
the overexpressed nuclear form of the SREBP-1c 
protein in transgenic livers (Figure 5).  Production 
of nuclear SREBP-1c was stabilized by the 
transgene under the control of the PEPCK 
promoter.  However, the amount of transgene 
SREBP-1c protein in liver nuclei was not elevated 
by Fbw7 knockdown, whereas c-Jun was 
accumulated (Figures 5A, 5B and 5C).  
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Expression of SREBP-1c target genes such as 
FAS and SCD1 was not elevated consistently 
(Figure 5D). Nevertheless, after Fbw7i treatment, 
increased TG content was elevated further, and 
PPARγ2 expression was markedly up-regulated in 
SREBP-1c transgenic livers to the same extent as 
in wild-type livers (Figures 5E and 5F).  These 
data suggested that Fbw7 knockdown did not 
affect the stability of the hepatic nuclear 
SREBP-1c protein in vivo.  To directly evaluate 
the effects of Fbw7 knockdown on the uptake of 
fatty acids, mouse primary hepatocytes were 
prepared and infected with Fbw7i (Figure 6).  
Direct Fbw7 knockdown in primary hepatocytes 
increased the expression of PPARγ2 and CD36 
(Figures 6A, 6B and 6C), leading to an increase in 
the estimated uptake of fatty acids (Figure 6D). 
 Conversely, the effects of Fbw7α overexpression 
were tested (Figure 7).  After the adenoviral 
overexpression of Fbw7α, liver weight was 
slightly but significantly reduced, while the 
change in liver TG content was not significant 
(Figures 7A, 7B, and 7C).  Adenoviral 
overexpression of Fbw7α decreased c-Jun and its 
phosphorylated protein, but not its mRNA, 
confirming the enhancement of Fbw7 activity.  
Meanwhile, Fbw7α overexpression caused 
parallel decreases in SREBP-1c mRNA as well as 
precursor and nuclear proteins (Figures 7D, 7E, 
and 7F). This finding does not support the 
enhancement of SREBP-1c protein degradation by 
Fbw7α in vivo.  In contrast, Fbw7α 
overexpression suppressed the expression of 
PPARγ2 and its target genes CD36, DGAT1/2, 
and Fsp27, but not GPAT as an SREBP-1 target 
(Figures 7G and 7H).  mRNA levels of HMGCR 
and LDLR genes were not affected (data not 
shown). Overall, the effects of Fbw7 
overexpression were consistently opposed to its 
inhibition, including the absence of an impact on 
SREBP-1c. 
 To confirm that PPARγ2 was responsible for the 
Fbw7α-mediated regulation of hepatic TG 
metabolism, PPARγ2 knockdown was 
superimposed onto Fbw7α knockdown in fatty 
liver (Figure 8).  In double-knockdown animals, 
the induction of PPARγ2 expression by Fbw7α 
knockdown (roughly 50% inhibition) was 
completely suppressed to the baseline level of the 
LacZi control (Figures 8A and 8B).  As a result, 
the elevation of PPARγ2 target genes such as 
CD36, DGAT1, and Fsp27 by Fbw7α knockdown 
was also inhibited completely by PPARγ2 
knockdown, and the elevation of hepatic TG 
content by Fbw7 knockdown decreased 
considerably (Figures 8C and 8D).  These data 
indicated that PPARγ2 mediated hepatic TG 
accumulation in the absence of Fbw7α. 
 PPARγ2 is not regarded as a direct target protein 
of Fbw7-mediated degradation because its 
10 
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expression is repressed by Fbw7α at the 
transcriptional level. Moreover, the protein lacks 
the Cdc4 phosphodegron (CPD) consensus (2) in 
its amino acid sequence as an Fbw7 target.  
CCAAT/enhancer binding protein (C/EBP) β and 
KLF5 are known as the transcription factors 
involved in PPARγ2 expression (41,42).  KLF5 
has been reported as a new target of Fbw7 (43,44), 
and KLF5, but not C/EBPβ, which has the CPD 
consensus in its amino acid sequence (Figure 9A). 
Adenoviral knockdown or overexpression of 
Fbw7α consistently up-regulated or suppressed 
KLF5, respectively (Figure 9B), but not C/EBPβ, 
as estimated by immunoblot analysis of mouse 
hepatic proteins (data not shown).  
Fbw7α-mediated degradation of KLF5 was 
investigated using the cycloheximide chase assay 
in Cos-7 cells.  Fbw7α enhanced the degradation 
of the KLF5 protein (Figure 9C).  This 
degradation of the KLF5 protein by Fbw7α was 
inhibited by the proteasome inhibitor ALLN in a 
way similar to the degradation of the SREBP-1 
protein by Fbw7α (Figures 9D and 9E).  These 
data confirmed KLF5 as an Fbw7 target.  Finally, 
the contribution of KLF5 to the Fbw7–PPARγ2 
pathway was estimated using primary hepatocytes 
from KLF5 flox mice (Figure 10).  Treatment of 
KLF5 flox hepatocytes with recombinant 
adenovirus expressing Cre recombinase (Ad-Cre) 
led to the essential deletion of KLF5 mRNA 
(Figure 10A).  KLF5-deleted hepatocytes 
decreased PPARγ2 expression, establishing KLF5 
as an upstream transcription factor of PPARγ2.  In 
control hepatocytes infected with Ad-GFP, 
PPARγ2 expression was increased by Fbw7i, as 
observed in vivo and returned to the basal level 
with KLF5 deletion (Figures 10B and 10C). These 
findings demonstrated that KLF5 mediates the 
Fbw7–PPARγ2 pathway.  
 To reveal the pathophysiological situation where 
Fbw7α regulates PPARγ2, we tested the effect of 
PPARα activation on pathological fatty liver.  
Obese mice such as db/db or ob/ob mice with 
leptin deficiency, exhibited severe hepatosteatosis 
with marked induction of PPARγ2 (42,45).  
Fibrates that have a PPARα agonist action 
ameliorate fatty liver associated with a reduction 
in PPARγ2. The mechanism for this action has yet 
to be determined (46).  In db/db mice, the level of 
nuclear Fbw7 protein was low, while KLF5 
protein level was high compared with the control 
C57BL/6 mice. This suggests that Fbw7 
contributes to PPARγ2 regulation (data not 
shown).  Furthermore, ob/ob mice were treated 
with fenofibrate, and this system was examined 
(Figure 11).  Interestingly, the PPARα agonist 
caused strong induction of the nuclear Fbw7 
protein, accompanied by a reduction in the KLF5 
protein (Figure 11A). This explains the 
suppression of PPARγ2 and TG content by 
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PPARα activation (Figures 11B and 11C). 
 
Discussion 
 
Previous in vitro studies have suggested that Fbw7 
is involved in the degradation of the nuclear 
SREBP protein (14).  The present study was 
conducted to estimate the role of Fbw7 on the 
SREBP-1c system for lipogenesis in vivo.  
Unexpectedly, neither knockdown nor 
overexpression of Fbw7α contributed to 
SREBP-1c protein levels in livers although our 
experimental settings on Fbw7 perturbation were 
strong enough for c-Jun, another target of Fbw7α.  
No impact of Fbw7α was observed on the nuclear 
SREBP-1c protein in the liver for a wide range of 
amounts of nuclear SREBP-1c protein in both 
wild type and SREBP-1c transgenic mice livers. 
This finding discounts the possibility of Fbw7α 
contributing to in vivo regulation of liver 
SREBP-1c.  The precise molecular mechanism for 
this discrepancy between in vitro and in vivo data 
is currently unknown.  It has been proposed that 
the regulation of SREBP-1a stability by Fbw7α in 
cultured cells may be related to the cell cycle and 
growth (14).  In our experimental setting of Cos-7 
cells, the impacts of Fbw7α and the proteasome 
inhibitor ALLN on SREBP-1 proteins were also 
observed (Figure 9D).  However, the cell 
growth-linked Fbw7α/SREBP system may not 
work in the liver, considering the long doubling 
time of hepatocytes.   
 The present findings demonstrated that Fbw7α 
regulated TG metabolism in the liver.  The gene 
expression pattern in Fbw7α-knockdown livers 
indicated that Fbw7 regulated fatty acid uptake 
and TG synthesis, but not fatty acid synthesis or 
degradation, thereby highlighting the linkage of 
PPARγ2 and its target genes CD36, DGAT1, and 
Fsp27.  In addition, the present study emphasized 
the physiological role of hepatic PPARγ2 in 
normal nutrition.  In contrast to adipose tissue, 
PPARγ2 expression is low in the livers of mice on 
a normal diet.  The suppression of PPARγ2 by 
Fbw7α may contribute to this regulation and 
prevent unnecessary accumulation of 
hepatosteatosis during a normal energy state. 
PPARγ2 is induced and involved in liver TG 
content in pathological fatty liver such as in ob/ob 
and diet-induced obesity (DIO) mice (47-50).  
However, hepatic Fbw7α expression increased 
slightly under these conditions of overnutrition 
(data not shown).  Fbw7α overexpression had no 
effect on fatty liver in ob/ob mice.  Fbw7α did not 
appear to have a crucial effect on the regulation of 
liver TG content in overnutrition, where PPARγ2 
induction occurs mainly through the 
trans-activation of C/EBPα and β (42).  In contrast, 
PPARα ameliorated fatty liver in these mice with 
a reduction in PPARγ2.  Our data indicated that 
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Fbw7 may mediate this inhibitory action of 
PPARα on PPARγ2 and hepatosteatosis. 
 PPARγ2 is related to insulin resistance in ob/ob 
and DIO mice (48,49).  Overexpression of 
PPARγ2 in livers ameliorated insulin resistance 
and decreased plasma levels of glucose and 
insulin in DIO mice, while ablation of PPARγ2 in 
ob/ob mice resulted in severe insulin resistance 
and an increase in plasma glucose levels.  In the 
present study, significant decreases in plasma 
glucose and insulin were observed in Fbw7 
knockdown mice, indicating that insulin 
sensitivity may be enhanced by up-regulation of 
hepatic PPARγ2 expression (Table 1).  
 Furthermore, our findings indicated that KLF5 
was a direct target of Fbw7 in vivo and in vitro.  
Based on the data from KLF5-deleted hepatocytes, 
KLF5 could at least partially explain PPARγ2 
up-regulation by suppression of hepatic Fbw7α.  
As shown in Figure 10, the induction of PPARγ2 
by Fbw7 knockdown was markedly impaired but 
slightlyremained in KLF5-deleted hepatocytes. 
This indicates that there could be some 
KLF5-independent mechanism.  Careful 
interpretation of this molecular process is required 
as KLF5 may have various biological effects on 
cell growth (51,52) and secondary metabolic 
disturbances.  Based on previous reports that 
c-Myc overexpression in transgenic mice 
contributed to glucose metabolism (53,54), it is 
possible that c-Myc, potentially induced by Fbw7i, 
could be involved in steatosis in 
Fbw7-knockdown livers. 
 Fbw7 is thought to be a cell growth regulator.  
The present study demonstrated an association of 
Fbw7 with hepatic fatty acid uptake and TG 
synthesis through PPARγ2 and not with 
lipogenesis through SREBP-1c.  Further 
investigations are necessary to elucidate the 
precise roles of this versatile factor in light of the 
association between the nutritional regulation of 
lipid metabolism and regulation of cell growth. 
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Figure Legends 
 
FIGURE 1.  In vivo effects of Fbw7 knockdown in livers of C57BL/6J mice.  Eight- to 
nine-week-old male C57BL/6J mice were infected through the tail vein with adenovirus encoding 
RNAi targeting Fbw7 (Fbw7i) or LacZ (LacZi) sequences (adenoviral dose of 2.5 × 1011 viral 
particles per mouse).  After 4 days of standard chow feeding, the mice were sacrificed in the 
non-fasted state. 
A: Fbw7 mRNA levels in the livers of mice infected with LacZi or Fbw7i, as determined by real-time 
PCR (graph) or northern blot analysis (insert).  The quantities of mRNA were calculated as the ratio 
of the cyclophilin level in each cDNA sample.  Data are shown as the expression ratio relative to the 
LacZi control group.  B: Abdominal (top) and hepatic (bottom) views of mice infected with LacZi or 
Fbw7i.  Liver weights (C), epididymal white adipose tissue (WAT) weights (D), liver histology 
(hematoxylin and eosin staining, × 200) (E), liver triglyceride (TG) contents (F), and liver total 
cholesterol (TC) contents (G) of mice infected with LacZi or Fbw7i. n = 9 per group in (A), (C), (D), 
and (F), and n = 4 per group in (G).  Statistical analysis was performed using unpaired Student’s 
t-test; ** p < 0.01 (versus LacZi control group). 
 
FIGURE 2.  Effects of Fbw7 knockdown on the protein and mRNA expression in the livers of 
C57BL/6J mice.  All mice were infected with Fbw7i or LacZi adenovirus. After 4 days of standard 
chow feeding the mice were sacrificed in the non-fasted state. 
A: Immunoblot analysis of the cleaved nuclear forms of SREBP-1 (nSREBP-1), c-Jun, 
phosphorylated c-Jun (P-c-Jun), and Lamin A/C as an internal control in nuclear extracts and 
precursor forms of SREBP-1 (pSREBP-1) and α-tubulin as an internal control in whole cell lysates 
from mouse livers.  Each protein sample was obtained from 3–5 mice infected with LacZi or Fbw7i.  
Protein levels of the Fbw7i group displayed below each blot are shown as the mean ± SEM of the 
relative quantity ratios to the LacZi control group in 3–5 independent experiments.  The protein 
quantities were determined as described in the experimental procedures and normalized by the 
respective internal control.  B: mRNA levels of cJun.  C: mRNA levels of SREBP-1c, acetyl-CoA 
carboxylase (ACC), fatty acid synthase (FAS), long chain fatty acid elongase 6 (Elovl6), 
stearoyl-CoA desaturase (SCD) 1, and carbohydrate responsive element binding protein (ChREBP).  
D: mRNA levels of PPARα and its regulated genes acyl-CoA oxidase (ACO) and medium chain 
acyl-CoA dehydrogenase (MCAD).  mRNA levels of PPARγ1, PPARγ2, aP2 (E), and CD36, 
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mitochondrial glycerol-3-phosphate acyltransferase (GPAT), diacylglycerol acyltransferase 1/2 
(DGAT1/2), and fat-specific protein 27 (Fsp27) (F).  All RNA samples were extracted from the livers 
of mice infected with LacZi or Fbw7i.  The quantities of mRNA were determined by real-time PCR 
and normalized by the cyclophilin level in each cDNA sample.  mRNA levels are shown as the 
expression ratio relative to the LacZi control group.  n = 3–5 per group in (A), n = 4–9 per group in 
(C) and (F), n = 4 per group in (B) and (D), and n = 7–9 per group in (E).  Statistical analysis was 
performed using one sample t-test in (A) and unpaired Student’s t-test in all other panels; ** p < 0.01 
and * p < 0.05 (versus LacZi control group). 
 
FIGURE 3.  Effects of Fbw7 knockdown on gene expression in the livers of C57BL/6J mice.  All 
mice were infected with Fbw7i or LacZi adenovirus. After 4 days of standard chow feeding the mice 
were sacrificed in the non-fasted state. 
mRNA levels of LDL receptor (LDLR) and HMG-CoA reductase (HMGCR) (A), apolipoprotein B 
(ApoB) and microsomal triglyceride transfer protein (MTTP) (B), glucose-6-phosphatase (G6Pase), 
phosphoenolpyruvate carboxykinase (PEPCK), glucose transporter 2 (GLUT2), and glucokinase (GK) 
(C), and IL-1β and IL-6 (D) in the livers of mice infected with LacZi or Fbw7i determined by 
real-time PCR.  The quantities of mRNA were calculated as the ratio of the cyclophilin level in each 
cDNA sample. mRNA levels are shown as the expression ratio relative to the LacZi control group.  n 
= 4 per group in (A) and (C), and n = 8 or 9 per group in (B) and (D).  Statistical analysis was 
performed using unpaired Student’s t-test; ** p < 0.01 and * p < 0.05 (versus LacZi control group). 
 
FIGURE 4.  Effects of Fbw7 knockdown on gene expression and TG contents in the livers of 
SREBP1-KO.  Six- to eight-week-old male SREBP1-KO and littermates were infected through the 
tail vein with Fbw7i or LacZi adenovirus (adenoviral dose of 2.5 × 1011 viral particles per mouse).  
After 4 days of standard chow feeding, the mice were sacrificed in the non-fasted state. 
A: Fbw7α mRNA levels in the livers of SREBP1-KO and littermates infected with LacZi or Fbw7i  
determined by real-time PCR.  B: Liver TG contents of SREBP1-KO and littermates infected with 
LacZi or Fbw7i.  C: Immunoblot analysis of cleaved nSREBP-1, c-Jun, P-c-Jun, and Lamin A/C as an 
internal control in nuclear extracts from the livers of 4 or 5 mice in each group indicated. 
Quantification results were obtained as described in the experimental procedures and normalized by 
the internal control. Relative changes compared to controls (littermates infected with LacZi) are 
displayed below each blot.  The mRNA levels of FAS and SCD1 (D), HMG-CoA reductase 
(HMGCR) (E), and PPARγ2 and CD36 (F) in the livers of SREBP1-KO and littermates infected with 
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LacZi or Fbw7i.  The quantities of mRNA were determined by real-time PCR and normalized by the 
cyclophilin level in each cDNA sample.  mRNA levels were shown as the expression ratio relative to 
the LacZi control group.  n = 4 or 5 per group in all panels.  Statistical analysis was performed using 
unpaired Student’s t-test; ** p < 0.01 (versus respective LacZi control group). 
 
FIGURE 5.  Effects of Fbw7 knockdown on gene expression and TG contents in the livers of 
SREBP-1c transgenic mice (SREBP1c-Tg).  Thirteen-week-old male SREBP1c-Tg and littermates 
were infected through the tail vein with Fbw7i or LacZi adenovirus (adenoviral dose of 2.5 × 1011 
viral particles per mouse).  After 4 days of standard chow feeding, the mice were sacrificed in the 
non-fasted state. 
A: Fbw7a mRNA levels in the livers of SREBP1c-Tg and littermates infected with LacZi or Fbw7i.  
B: Immunoblot analysis of the cleaved nuclear forms of SREBP-1 (nSREBP1), c-Jun, and Lamin A/C 
as an internal control in nuclear extracts from the livers of 5 mice in each group indicated.  
Quantification results were obtained as described in the experimental procedures and normalized by 
the internal control. Relative changes compared to controls (littermates or SREBP1c-Tg infected with 
LacZi) are displayed below each blot.  mRNA expression of exogenous human SREBP-1c 
(hSREBP-1c) (C) and FAS and SCD1 (D) in the livers of SREBP1c-Tg and littermates infected with 
LacZi or Fbw7i.  ND, not detected.  E: Liver TG contents of SREBP1c-Tg and littermates infected 
with LacZi or Fbw7i.  F: mRNA levels of PPARγ2 in the livers of SREBP1c-Tg and littermates 
infected with LacZi or Fbw7i.  mRNA quantities were determined by real-time PCR and calculated as 
the ratio of the cyclophilin level in each cDNA sample.  Data are shown as the expression ratio 
relative to the LacZi control group.  n = 5 per group in all panels.  Statistical analysis was performed 
using unpaired Student’s t-test; ** p < 0.01 and * p < 0.05 (versus respective LacZi control group). 
 
FIGURE 6.  Influence of Fbw7 knockdown on fatty acid uptake in mouse primary hepatocytes.  
Primary hepatocytes were isolated from C57BL/6J mice and infected with Fbw7i or LacZi adenovirus 
(1000 virus particles/cell) and cultured for 48 h. [1-14C]palmitate uptake of the treated primary 
hepatocytes was measured, as indicated in the experimental procedures. 
mRNA levels of Fbw7α (A), PPARγ2 (B), and CD36 (C) in mouse primary hepatocytes infected with 
LacZi or Fbw7i.  The quantities of mRNA were determined by real-time PCR and normalized by the 
cyclophilin level in each cDNA sample. mRNA levels are shown as the expression ratio relative to the 
LacZi control group.  D: [1-14C]palmitate incorporation into cellular lipid in mouse primary 
hepatocytes infected with LacZi or Fbw7i.  All experiments were performed using five sets of primary 
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hepatocytes for each group.  Statistical analysis was performed using unpaired Student’s t-test; ** p < 
0.01 (versus LacZi control group). 
 
FIGURE 7.  In vivo effects of Fbw7α overexpression in the livers of C57BL/6J mice.  
Fourteen-week-old male C57BL/6J mice were infected through the tail vein with adenovirus encoding 
GFP (Ad-GFP) as the control or mouse Fbw7α (Ad-Fbw7α) (adenoviral dose of 1.5 × 1011 viral 
particles per mouse).  After 6 days of standard chow feeding, the mice were sacrificed in the 
non-fasted state. 
A: mouse Fbw7α mRNA levels in livers of mice infected with Ad-GFP or Ad-Fbw7α determined by 
real-time PCR (graph) and Fbw7α protein levels, examined by immunoblot analysis (insert).  Liver 
weights (B) and liver TG contents (C) of the mice infected with Ad-GFP or Ad-Fbw7α.  D: 
Immunoblot analysis of cleaved nuclear forms of SREBP-1 (nSREBP-1), c-Jun, P-c-Jun, and Lamin 
A/C as an internal control in nuclear extracts, and precursor forms of SREBP-1 (pSREBP-1) and 
α-tubulin as an internal control in whole cell lysates from mouse livers.  Each protein sample was 
obtained from 3–5 mice infected with Ad-GFP or Ad-Fbw7α.  Protein levels of the Ad-Fbw7α group 
displayed below each blot are shown as the mean ± SEM of the relative quantity ratios to the Ad-GFP 
control group in 3 independent experiments.  The protein quantities were determined as described in 
the experimental procedures and normalized by the respective internal control.  The mRNA levels of 
SREBP-1c, ACC, FAS, Elovl6, and SCD1 (E), c-Jun (F), PPARγ1 and PPARγ2 (G), and CD36, 
GPAT, DGAT1/2, and Fsp27 (H) in the livers of mice infected with Ad-GFP or Ad-Fbw7α.  The 
quantities of mRNA were determined by real-time PCR and normalized by the cyclophilin level in 
each cDNA sample. The mRNA levels are shown as the expression ratio relative to the Ad-GFP 
control group.  n = 3 per group in (D) and n = 5 per group in all other panels.  Statistical analysis was 
performed using one sample t-test in (A) and unpaired Student’s t-test in all other panels; ** p < 0.01 
and * p < 0.05 (versus Ad-GFP control group). 
 
FIGURE 8.  Effects of Fbw7 and PPARγ2 double knockdown on gene expression and TG 
contents in the livers of C57BL/6J mice.  Nine-week-old male C57BL/6J mice were infected 
through the tail vein with adenovirus encoding RNAi targeting PPARγ2 (PPARγ2i), Fbw7 (Fbw7i), 
and/or LacZ (LacZi) sequence (adenoviral dose of 2.5 × 1011 viral particles per mouse).  After 4 days 
of standard chow feeding, the mice were sacrificed in the non-fasted state. 
The mRNA levels of Fbw7α (A), PPARγ1 and PPARγ2 (B), and CD36, DGAT1, and Fsp27 (C) in 
livers of mice treated with LacZi alone (LacZi), Fbw7i and LacZi (Fbw7i), or Fbw7i and PPARγ2i 
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(Fbw7i + PPARγ2i).  D: The liver TG contents of these three groups are as described above.  The 
quantities of mRNA were determined by real-time PCR and normalized by the cyclophilin level in 
each cDNA sample. mRNA levels are shown as the expression ratio relative to the LacZi control 
group.  n = 4 or 5 per group in all panels.  Statistical analysis was performed using two-way ANOVA 
followed by Tukey’s procedure; ** p < 0.01 and * p < 0.05 (versus LacZi) and ## p < 0.01 (versus 
Fbw7i). 
 
FIGURE 9.  Fbw7α-mediated degradation of Krüppel-like factor 5 (KLF5). 
A, Amino acid sequence alignment of the Cdc4 phosphodegron (CPD) in cyclin E, c-Myc, c-Jun, and 
KLF5.  B, Immunoblot analysis of KLF5 and Lamin A/C as an internal control in nuclear extracts 
from the livers of 4 or 5 mice infected with LacZi, Fbw7i, Ad-GFP (GFP), or Ad-Fbw7α (Fbw7α). 
Quantification results were obtained as described in the experimental procedures and normalized by 
the internal control. The changes relative to the controls (LacZi or GFP) are displayed below each blot.  
C: Cos-7 cells were transfected with KLF5 in the presence or absence of Fbw7α.  Thirty-six hours 
after transfection, the cells were either lysed directly or incubated in the presence of cycloheximide 
(100 µg/mL) for the time period indicated to determine KLF5 turnover.  The levels of KLF5 were 
determined by immunoblot analysis.  D: Cos-7 cells were transfected with the SREBP-1c expression 
plasmid in the presence or absence of Fbw7α.  Thirty-six hours after transfection, the cells were 
treated with vehicle alone (DMSO) or ALLN (50 µg/mL) for 4 h prior to cell lysis.  The protein levels 
of SREBP-1c, Fbw7α, and α-tubulin were determined by immunoblot analysis.  E: Cos-7 cells were 
transfected with the KLF5 expression plasmid in the presence or absence of Fbw7α.  Thirty-six hours 
after transfection, the cells were treated with vehicle alone (DMSO) or ALLN (50 µg/mL) for 4 h 
prior to cell lysis.  The protein levels of KLF5, Fbw7α, and α-tubulin were determined by immunoblot 
analysis. 
 
FIGURE 10.  Contribution of KLF5 to Fbw7-mediated inhibition of PPARγ2.  Primary 
hepatocytes prepared from KLF5 flox mice were seeded in 6-cm plates and infected with Fbw7i or 
LacZi (1000 virus particles/cell) and Ad-GFP as the control or Ad-Cre recombinase encoding 
adenovirus (Ad-Cre) (300 virus particles/cell).  Infected hepatocytes were cultured for 48 h, and the 
mRNA levels in treated hepatocytes determined by real-time PCR. 
The mRNA levels of KLF5 (A), Fbw7α (B), and PPARγ2 (C) in mouse primary hepatocytes infected 
with LacZi or Fbw7i and Ad-GFP or Ad-Cre.  The quantities of mRNA were determined by real-time 
PCR and normalized by the cyclophilin level in each cDNA sample. mRNA levels are shown as the 
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expression ratio relative to  both the LacZi- and Ad-GFP-infected control groups.  All experiments 
were performed using four sets of primary hepatocytes for each group.  Statistical analyses were 
performed using two-way ANOVA followed by Tukey’s procedure; * p < 0.05 (versus LacZi of each 
group) and # p < 0.05 (versus LacZi or Fbw7i of Ad-GFP group). 
 
FIGURE 11.  Effects of fenofibrate administration on gene expression and TG contents in the 
livers of ob/ob mice.  Eight-week-old male ob/ob mice were fed a control diet (ob/ob Feno(−)) or 
0.1% fenofibrate diet (ob/ob Feno(+)) for 7 days.  All mice were sacrificed in the non-fasted state. 
A: Immunoblot analysis of Fbw7α, KLF5, and Lamin A/C as an internal control in nuclear extracts 
from the livers of 5 mice in each group indicated.  Quantification results were obtained as described in 
the experimental procedures and normalized by the internal control. The changes relative to the 
controls (ob/ob Feno(−)) are displayed below each blot.  B: PPARγ2 mRNA levels in livers of ob/ob 
mice treated with control or 0.1% fenofibrate diet.  The quantities of mRNA were determined by 
real-time PCR and normalized by the cyclophilin level in each cDNA sample. mRNA levels are 
shown as the expression ratio relative to the ob/ob Feno(−) control group.  C: Liver TG contents of 
ob/ob mice treated with control or 0.1% fenofibrate diet.  n = 8 or 9 per group in (B) and n = 5 per 
group in (C).  Statistical analysis was performed using unpaired Student’s t-test; ** p < 0.01 and * p < 
0.05 (versus ob/ob Feno(−)). 
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TABLE 1 
Plasma metabolic parameters in the Fbw7 knockdown mice. 
Data are the mean ± SEM of 4 male C57BL/6J mice in the non-fasted state at day 4 after adenovirus 
infection. 
Parameter LacZi Fbw7i 
Body weight (g) 25.3 ± 0.47 24.6 ± 0.15 
Glucose (mg/dL) 252 ± 8.3 191 ± 14* 
Insulin (pg/mL) 0.30 ± 0.083 0.057 ± 0.036* 
TG (mg/dL) 151 ± 6.4 92 ± 1.2** 
TC (mg/dL) 67.4 ± 6.9 88.2 ± 6.7 
NEFA (mEq/L) 1.21 ± 0.04 1.14 ± 0.08 
ALT (Karmen unit) 30 ± 1.6 42 ± 1.0** 
AST (Karmen unit) 63 ± 4.8 114 ± 5.4** 
* p < 0.05 and ** p < 0.01 (versus each respective LacZi control). 
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Supplementary Table 1. Sequence of primers for quantitative real time-PCR 
Gene (mouse) Sequence of forward primer (5’ to 3’) Sequence of reverse primer (5’ to 3’) 
Cyclophilin 
Fbw7α 
SREBP1c 
ACC 
FAS 
Elovl6 
SCD1 
ChREBP 
LDLR 
HMGCR 
PPARα 
ACO 
MCAD 
PPARγ1 
PPARγ2 
CD36 
GPAT 
DGAT1 
DGAT2 
KLF5 
G6Pase 
PEPCK 
GLUT2 
GK 
c-Jun 
aP2 
IL-6 
IL-1β 
ApoB 
MTTP 
TGGCTCACAGTTCTTCATAACCA 
CTCACCAGCTCTCCTCTCCATT 
CGGCGCGGAAGCTGT 
GGGCACAGACCGTGGTAGTT 
ATCCTGGAACGAGAACACGATCT 
CCCGAACTAGGTGACACGAT 
AGATCTCCAGTTCTTACACGACCAC 
CTGGGGACCTAAACAGGAGC 
TGGAGGATGAGAACCGGCT 
GACAAGAAGCCTGCTGCCATA 
CCTCAGGGTACCACTACGGAGT 
CGATCCAGACTTCCAACATGAG 
TGCTTTTGATAGAACCAGACCTACAGT 
GCGGCTGAGAAATCACGTTC 
AACTCTGGGAGATTCTCCTGTTGA 
CCAAATGAAGATGAGCATAGGACAT 
GGCTACGTCCGAGTGGATTTT 
CGTGGTATCCTGAATTGGT 
ATCTTCTCTGTCACCTGGCT 
ACCTTACAGCATCAACATGAACG 
GGGCGCAGCAGGTGTATACTAT 
TGTCATCCGCAAGCTGAAGA 
GGAACCTTGGCTTTCACTGTCTT 
TCCCTGTAAGGCACGAAGACAT 
CCTTCTACGACGATGCCCTC 
TTTCCTTCAAACTGGGCGTG 
TAGTCCTTCCTACCCCAATTTCC 
GCAACTGTTCCTGAACTCAACT 
TTGGCAAACTGCATAGCATCC 
AGCTTTGTCACCGCTGTGC 
ATGACATCCTTCAGTGGCTTGTC 
GCTGAACATGGTACAAGGCCA 
TGCAATCCATGGCTCCGT 
CAGGATCAGCTGGGATACTGAGT 
AGAGACGTGTCACTCCTGGACTT 
CCAGCGACCATGTCTTTGTA 
CTTTCATTTCAGGACGGATGTCT 
GAAGCCACCCTATAGCTCCC 
GCACTGAAAATGGCTTCGTTTA 
CGTCAACCATAGCTTCCGTAGTT 
GCCGAATAGTTCGCCGAA 
CCATGGTGGCACTCTTCTTAACA 
CTTGGTGCTCCACTAGCAGCTT 
GAATATCAGTGGTTCACCGCTTC 
GAAGTGCTCATAGGCAGTGCAT 
GTTGACCTGCAGTCGTTTTGC 
AACATCATTCGGTCTTGAAGGAA 
GGCGCTTCTCAATCTGAAAT 
ACCTTTCTTGGGCGTGTTCC 
TGGCTGAAAATGGTAACAGGTT 
CAGAATCCCAACCACAAGATGA 
TTCGATCCTGGCCACATCTC 
GGAACACCCAAAACATGTCGAT 
ATTGCCACCACATCCATCTCA 
GGTTCAAGGTCATGCTCTGTTT 
AGGGTTATGATGCTCTTCACCTTC 
TTGGTCCTTAGCCACTCCTTC 
ATCTTTTGGGGTCCGTCAACT 
TCAAATTGGGACTCTCCTTTAGC 
TCCTGCTATGGTTTGTTGGAAGT 
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